Foundayo (orforglipron)
FDA approved for obesity on 2026-04-01; Q2 2026 revenue $98M; type 2 diabetes submitted in the US.
The numbers
What it is
Orforglipron, an oral small-molecule GLP-1 receptor agonist taken without food or water restrictions. It is the first oral obesity drug from Lilly and competes directly with Novo Nordisk's oral semaglutide.
Why it matters to the stock. Foundayo extends Lilly's incretin franchise into the oral market, where pricing and volume could differ sharply from injectables.
News
Foundayo ACHIEVE-4: MACE-4 non-inferiority met vs insulin glargine, not significant
Lilly reported detailed ACHIEVE-4 results for Foundayo on September 30, 2026, showing the oral GLP-1 met non-inferiority against insulin glargine on major adverse cardiovascular events.
UK MHRA approves Foundayo (orforglipron) for weight management and type 2 diabetes
The UK Medicines and Healthcare products Regulatory Agency authorised Lilly's oral GLP-1 Foundayo for weight management and for type 2 diabetes on August 10, 2026.
Medicare GLP-1 Bridge starts July 1 with $50 monthly copay for Zepbound and Foundayo
Eligible Medicare Part D patients can get Zepbound and Foundayo for weight management for $50 a month under the Medicare GLP-1 Bridge program, which started July 1, 2026.
FDA approves Foundayo, Lilly's oral GLP-1 pill, for adults with obesity
The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist taken without food or water restrictions, for adults with obesity and for adults with overweight who have at least one weight-related condition.